![DSpace logo](/jspui/image/logo.gif)
Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13423
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Taliyan, Rajeev | - |
dc.date.accessioned | 2023-12-14T07:15:50Z | - |
dc.date.available | 2023-12-14T07:15:50Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.uri | https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/80252 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13423 | - |
dc.description.abstract | Metabolic syndrome (MS) includes clusters of metabolic disorders and type 2 DM (T2DM) is most common MS which cause insulin resistance (IR). The IR mediated dysregulation of signaling cascades in brain increase the production and secretion of Aβ, p-tau which prompt to Alzheimer’s (AD). Therefore, repaglinide (REP) a meglitinides drug is used, which act by targeting ATP binding cassette and evidence indicated that REP increase neuronal survival via upregulating ATF-6 gene and blocking the DREAM. Thus, there is huge possibility that REP regulate and modulate the expression of pro-apoptotic protein, anti-apoptotic protein, calcium homeostasis and may eventually reduce the neuronal cell death. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Alzheimer's Association | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | Alzheimer's disease | en_US |
dc.subject | Chronic Traumatic Encephalopathy (CTE) | en_US |
dc.subject | Metabolic syndrome | en_US |
dc.title | Mechanistic Insights of Meglitinides Drug Repurposing and Delivery to Brain for Metabolic Syndrome Linked Neurodegenerative Disease | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.